Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the tuberculosis therapeutics market?

The market size of tuberculosis therapeutics has seen a significant upsurge in recent years. The growth will escalate from a value of $1.88 billion in 2024 to an increased value of $2.01 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.58%. The expansion in the past years is linked to the escalating prevalence of tuberculosis, the increasing uptake of tuberculosis therapeutics, heightened tuberculosis (TB) consciousness, a surge in XDR-TB cases, and a growing occurrence of drug-resistant tuberculosis.

What will be the tuberculosis therapeutics market size in the future?

Predictions for the tuberculosis therapeutics market size suggest robust growth in the immediate future, with an estimated value of $2.57 billion by 2029, reflecting a compound annual growth rate (CAGR) of 6.32%. The anticipated progression is contributed by factors such as escalated investments in the healthcare sector, heightened awareness and education levels, increased funding for research and development, more product approvals for anti-tuberculosis agents, and a rise in the geriatric population. The forecast period also foresees trends like advancements in drug development, the dawn of personalized medicine and combination therapies, the integration of digital health solutions, and the usage of artificial intelligence and machine learning in drug discovery.

Get your tuberculosis therapeutics market report here!

https://www.thebusinessresearchcompany.com/report/tuberculosis-therapeutics-global-market-report

What main drivers are fueling expansion in the tuberculosis therapeutics market?

The escalation of co-infection rates for tuberculosis and HIV (TB-HIV) is anticipated to bolster the tuberculosis therapeutics market’s expansion. The co-infection rate for TB-HIV is the proportion of people concurrently infected with tuberculosis and the human immunodeficiency virus. The rise in TB-HIV co-infections is seen as a result of the immune system being undermined by HIV, heightening susceptibility to tuberculosis, and both of these global epidemics’ overlap in high-risk demographic groups. Tuberculosis treatments aid in addressing the surge in TB-HIV co-infections by offering specific therapies that tackle both TB infection and HIV-induced immune system suppression, thus elevating the overall patient prognosis and lessening the impact of both illnesses. For example, as per data from gov.uk, a public sector in the UK, in October 2023, it was reported that there were 3,805 new HIV diagnoses in England in 2022, indicating a 22% rise from the 3,118 cases noted in 2021. Consequently, the tuberculosis therapeutics market’s growth is being propelled by the increasing TB-HIV co-infection rates.

What key areas define the segmentation of the global tuberculosis therapeutics market?

The tuberculosis therapeutics market covered in this report is segmented –

1) By Type: Active Tuberculosis (TB), Latent Tuberculosis (TB)

2) By Product Type: Isoniazid, Rifampin, Pyrazinamide, Hydrazine derivatives, Miscellaneous anti-tubercular drugs, Ethambutol

3) By Route of Administration: Oral, Parenteral, Other route of administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Active Tuberculosis (TB): First-Line Drugs (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol), Second-Line Drugs (Fluoroquinolones, Aminoglycosides), Combination Therapies, Drug-Resistant TB Treatments (MDR-TB, XDR-TB)

2) By Latent Tuberculosis (TB): Isoniazid Prophylaxis, Rifampicin-Based Regimens, Rifapentine-Based Regimens, Combination Prophylactic Therapies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20983&type=smp

Who are the dominant players expanding their reach in the tuberculosis therapeutics market?

Major companies operating in the tuberculosis therapeutics market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Macleods Pharmaceuticals Ltd., Cipla Limited, Hikma Pharmaceuticals plc, Lupin Limited, Alkem Laboratories Limited, Emcure Pharmaceuticals Limited, Otsuka Pharmaceutical Co. Ltd., Sequella Inc.

What are the key trends shaping the future of the tuberculosis therapeutics market?

Major companies operating in the tuberculosis therapeutics market are focusing on developing innovative solutions, such as combination therapy, to improve treatment efficacy, reduce the duration of therapy, and combat drug-resistant strains of tuberculosis. Combination therapy refers to the use of two or more medications from different classes to treat a disease, aiming to increase treatment efficacy, reduce resistance, and improve patient outcomes. For instance, in July 2024, Johnson & Johnson, a US-based pharmaceutical company, achieved a significant milestone in tuberculosis treatment with the approval of SIRTURO (bedaquiline) by both the U.S. FDA and the European Commission. This innovative drug is the first in over four decades specifically designed to target multidrug-resistant tuberculosis (MDR-TB). Its unique mechanism of action, inhibiting the ATP synthase enzyme essential for TB bacteria’s energy production, thereby offering a targeted and effective therapeutic approach. Its inclusion in combination therapies enhances the overall efficacy of MDR-TB regimens, reducing treatment duration and improving patient compliance.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20983

Which regions are emerging as leaders in the tuberculosis therapeutics market?

North America was the largest region in the tuberculosis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tuberculosis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Traffic Signals Global Market Report 2025

https://thebusinessresearchcompany.com/report/traffic-signals-global-market-report

Space Traffic Management Global Market Report 2025

https://thebusinessresearchcompany.com/report/space-traffic-management-global-market-report

Vessel Traffic Management Global Global Market Report 2025

https://thebusinessresearchcompany.com/report/vessel-traffic-management-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: